摘要
目的系统评价索拉非尼联合经皮肝动脉化疗栓塞术(TACE)治疗晚期肝细胞癌的疗效与安全性。方法计算机检索PubMed(1966年-2012年9月)、Embase(1990年-2012年9月)、中国期刊全文数据库(1994年-2012年9月)、中国生物医学文献数据库(1978年-2012年9月)、中文科技期刊数据库(1989年-2012年9月)、中华医学会数字化期刊库(1997年-2012年9月),同时手检相关期刊和会议论文集,纳入有关索拉非尼治疗晚期肝细胞癌的随机对照试验,按Cochrane系统评价方法提取资料、评价文献质量并进行统计学分析,数据采用RevMan 5.0软件进行分析。结果最终纳入7个随机对照试验,共854例患者。与索拉非尼组相比,索拉非尼联合TACE组能够延长肝癌患者的总生存期,但是不能降低病死率,手足反应、腹泻、皮疹、高血压的发生率增加,脱发的发生率没有差异。结论索拉非尼联合TACE治疗晚期肝细胞癌有效而安全。
Objective To evaluate the effectiveness and toxicities of sorafenib combined with thanscatheter artierial chemoembolzation （ TA-CE） in the treatment of advanced hepatocellular carcinoma （HCC）. Methods According to the Cochrane handbook for systematic review, two reviewers independently completed the whole process of literature search, study selection, data collection, and quality assessment. A manual and computerized search was performed using the PubMed, Embase, Chinese Journal Full - text Database, Chinese Biomedical Lit-erature Database, VIP Database for Chinese Technical Periodicals, and Chinese Medical Association Digital Periodicals to collect randomized controlled trials （RCT） of sorafenib in the treatment of advanced HCC published up to September 2012. The obtained data were analyzed with RevMan 5.0 software. Results Seven RCT involving 854 patients were finally included. Compared with sorafenib alone, sorafenib combined with TACE significantly prolonged the overall survival in HCC patients, but failed to reduce their mortality. The incidence of hand - foot syndrome, diarrhea, rash, and hypertension was significantly higher in combined treatment groups than in control groups, but the in-cidence of alopecia showed no significant difference between them. Conclusion Sorafenib combined with TACE are effective and safe in the treatment of advanced HCC.
出处
《临床肝胆病杂志》
CAS
2013年第10期764-768,共5页
Journal of Clinical Hepatology
